🎉 M&A multiples are live!
Check it out!

OSE Immunotherapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for OSE Immunotherapeutics and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

OSE Immunotherapeutics Overview

About OSE Immunotherapeutics

OSE Immunotherapeutics SA is a France-based biotechnology company focused on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. The product portfolio of the company comprises Tedopi, OSE-172, OSE-703, FR104 and OSE-127.


Founded

2016

HQ

France
Employees

40

Website

ose-immuno.com

Financials

LTM Revenue $76.0M

LTM EBITDA $39.1M

EV

$96.6M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

OSE Immunotherapeutics Financials

OSE Immunotherapeutics has a last 12-month revenue of $76.0M and a last 12-month EBITDA of $39.1M.

In the most recent fiscal year, OSE Immunotherapeutics achieved revenue of $2.4M and an EBITDA of -$18.8M.

OSE Immunotherapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See OSE Immunotherapeutics valuation multiples based on analyst estimates

OSE Immunotherapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $19.7M $2.4M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$14.1M -$18.8M XXX XXX XXX
EBITDA Margin -72% -786% XXX XXX XXX
Net Profit -$18.1M -$19.1M XXX XXX XXX
Net Margin -92% -797% XXX XXX XXX
Net Debt n/a $15.8M XXX XXX XXX

Financial data powered by Morningstar, Inc.

OSE Immunotherapeutics Stock Performance

As of April 15, 2025, OSE Immunotherapeutics's stock price is EUR 6 (or $6).

OSE Immunotherapeutics has current market cap of EUR 122M (or $131M), and EV of EUR 89.9M (or $96.6M).

See OSE Immunotherapeutics trading valuation data

OSE Immunotherapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$96.6M $131M XXX XXX XXX XXX $1.56

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

OSE Immunotherapeutics Valuation Multiples

As of April 15, 2025, OSE Immunotherapeutics has market cap of $131M and EV of $96.6M.

OSE Immunotherapeutics's trades at 1.3x LTM EV/Revenue multiple, and 2.5x LTM EBITDA.

Analysts estimate OSE Immunotherapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for OSE Immunotherapeutics and 10K+ public comps

OSE Immunotherapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $96.6M XXX XXX XXX
EV/Revenue 40.4x XXX XXX XXX
EV/EBITDA -5.1x XXX XXX XXX
P/E -5.3x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -4.5x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get OSE Immunotherapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

OSE Immunotherapeutics Valuation Multiples

OSE Immunotherapeutics's NTM/LTM revenue growth is -43%

OSE Immunotherapeutics's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.7M for the same period.

Over next 12 months, OSE Immunotherapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate OSE Immunotherapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for OSE Immunotherapeutics and other 10K+ public comps

OSE Immunotherapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -88% XXX XXX XXX XXX
EBITDA Margin -786% XXX XXX XXX XXX
EBITDA Growth 33% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -829% XXX XXX XXX XXX
Revenue per Employee $0.1M XXX XXX XXX XXX
Opex per Employee $0.7M XXX XXX XXX XXX
S&M Expenses to Revenue 3% XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 770% XXX XXX XXX XXX
Opex to Revenue 1135% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

OSE Immunotherapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

OSE Immunotherapeutics M&A and Investment Activity

OSE Immunotherapeutics acquired  XXX companies to date.

Last acquisition by OSE Immunotherapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . OSE Immunotherapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by OSE Immunotherapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About OSE Immunotherapeutics

When was OSE Immunotherapeutics founded? OSE Immunotherapeutics was founded in 2016.
Where is OSE Immunotherapeutics headquartered? OSE Immunotherapeutics is headquartered in France.
How many employees does OSE Immunotherapeutics have? As of today, OSE Immunotherapeutics has 40 employees.
Who is the CEO of OSE Immunotherapeutics? OSE Immunotherapeutics's CEO is Mr. Nicolas Poirier, PhD.
Is OSE Immunotherapeutics publicy listed? Yes, OSE Immunotherapeutics is a public company listed on PAR.
What is the stock symbol of OSE Immunotherapeutics? OSE Immunotherapeutics trades under OSE ticker.
When did OSE Immunotherapeutics go public? OSE Immunotherapeutics went public in 2015.
Who are competitors of OSE Immunotherapeutics? Similar companies to OSE Immunotherapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of OSE Immunotherapeutics? OSE Immunotherapeutics's current market cap is $131M
What is the current revenue of OSE Immunotherapeutics? OSE Immunotherapeutics's last 12-month revenue is $76.0M.
What is the current EBITDA of OSE Immunotherapeutics? OSE Immunotherapeutics's last 12-month EBITDA is $39.1M.
What is the current EV/Revenue multiple of OSE Immunotherapeutics? Current revenue multiple of OSE Immunotherapeutics is 1.3x.
What is the current EV/EBITDA multiple of OSE Immunotherapeutics? Current EBITDA multiple of OSE Immunotherapeutics is 2.5x.
What is the current revenue growth of OSE Immunotherapeutics? OSE Immunotherapeutics revenue growth between 2023 and 2024 was -88%.
Is OSE Immunotherapeutics profitable? Yes, OSE Immunotherapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.